Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA – Get Free Report) have earned a consensus rating of “Buy” from the seven brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $42.75.
KLRA has been the subject of several research analyst reports. Jefferies Financial Group assumed coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They issued a “buy” rating and a $48.00 price objective for the company. Evercore began coverage on shares of Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating on the stock. Zacks Research raised shares of Kailera Therapeutics to a “hold” rating in a research note on Wednesday, May 13th. William Blair began coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating for the company. Finally, Leerink Partners assumed coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 price objective for the company.
Read Our Latest Stock Report on Kailera Therapeutics
Kailera Therapeutics Price Performance
Kailera Therapeutics (NASDAQ:KLRA – Get Free Report) last posted its quarterly earnings results on Tuesday, May 26th. The company reported ($3,650.00) EPS for the quarter.
Kailera Therapeutics Company Profile
We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.
See Also
- Five stocks we like better than Kailera Therapeutics
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Receive News & Ratings for Kailera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kailera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
